The goal of this project is to use a crowd-based competition framework to develop a validated molecular predictor of anti-TNF response in RA. There is an increasing need for predictors of response to therapy in inflammatory disease driven by the observation that most clinically defined diseases show variable response and the growing availability of alternative therapies. Anti-TNF drugs in Rheumatoid Arthritis represent a prototypical example of this opportunity. A number of studies have tried, over the past decade, to develop a robust predictor of response. We believe the time is right to try a different approach to developing such a biomarker with a crowd-sourced collaborative competition. This is based on DREAM and Sage Bionetworks’ experience with running competitions and the availability of new unpublished large-scale data relating to RA treatment response.